Clinical Trial

Perimenstrual Symptoms and Emotional Dysregulation in Autism

Study acronym: MEDEA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Emotional dysregulation (ED) is defined by difficulties in modulating the experience and expression of emotions, which are characterized by particularly marked reactivity, intensity, and duration. To improve the understanding of ED, its consequences in autistic women, and to be able to offer them appropriate treatments, it seems crucial to investigate the links between ED, known adversities during childhood, and premenstrual dysphoric symptoms. This study aims to characterize the variability of ED throughout a menstrual cycle by measuring it in an ecological real-life context. The variability of ED will be compared to that of women with borderline personality disorder (BPD), women with premenstrual dysphoric disorder (PMDD), and women without a diagnosed disorder.
Protocol Amendment History 1 change
notable Primary completion pushed: 2029-04-01 -> 2029-05-01 2026-05-13
Trial Details
NCT Number NCT06871345
Lead Sponsor University Hospital, Strasbourg, France
Conditions Autism Spectrum Disorder, Borderline Personality Disorder BPD, a Premenstrual Dysphoric Disorder (PMDD)
Enrollment 90 participants
Start Date 2026-05-01
Primary Completion 2029-05-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-12